Slide 1: Managing Director Report, 6 Months to 31 Jan 2020
For personal use only Managing Director Report 6 Months to 31 Jan 2020 25 March 2020
Slide 2: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to adults, infants and children. 1
Slide 3: COVID-19 Update
COVID-19 Update For personal use only No disruption to customer Minimal disruption to sea order patterns freight High inventory position can Clover has implemented satisfy short and medium HR policy of split shifts and term demand working from home to separate staff No disruption to ingredient
Slide 4: Half Year Performance Highlights
Half Year Performance Highlights For personal use only Net Profit $4.6m up Preserving cash; no interim dividend 3.4% on half year 2019 Operating Revenue New products and $37.6m up 9.8% on customers delivering growth in USA, Europe, half year 2019 ANZ Operating expenses of Strategic increase in
Slide 5: Half Year 2020 Results
For personal use only Half Year 2020 Results AUD million 31 Jan 2020 31 Jan 2019 • 9.8% half year on half year revenue growth Revenue $37.6 $34.3 • Australia/NZ, USA & EU sales NPBT $6.4 $6.2 growth Tax ($1.7) ($1.7) NPAT $4.6 $4.5 • NPAT result $4.6m (PCP $4.5m) EPS 2.79 cps 2.71 cps ROE 20% 23% (a
Slide 6: Balance Sheet January 2020
Balance Sheet 31 January 2020 For personal use only AUD million Reported Reported Movement 31 Jan 2020 31 Jul 2019 Cash ($0.1) $8.3 ($8.4) Trade $13.7 $18.4 ($4.7) Receivables • Strategic increase Inventories $36.6 $27.7 $8.9 in Inventories to Total Current $50.7 $55.4 ($4.7) increase flexibility As
Slide 7: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Focus on Infant Formula New New Product Market Development Development 5
Slide 8: Growth Platform: Focus on Infant Formula
Focus on Infant Formula For personal use only Growth Platform Focus on the infant formula market Additional infant formula customers added in the half year and growth of existing business European customers prepare for the new EU regulation to include a minimum 20mg/100Kcal of DHA in infant form
Slide 9: Growth Platform: Creating new opportunities
For personal use only Growth Platform Creating new opportunities New products delivering sales across a range of applications in gummies, pressed tablets and health bars Sales in the USA up 57% v 1HFY19 New products are gaining attention across the fortified food market as companies look to de
Slide 10: Growth Platform: Expanding our market reach
For personal use only Growth Platform Expanding our market reach Strong 1H 20 on 1H19 growth in Aust/NZ 21%, USA 57% and Europe 31% with a decline in Asia (17%) driven by transfer of production from Asian to Aust/NZ facilities (up 21%) Strengthening face to face selling teams in EU, Asia & China
Slide 11: 2HFY2020 Outlook & Priorities
2HFY2020 Outlook & Priorities For personal use only • Continue to develop opportunities in the EU • Complete build and qualification of Melody Dairies NZ spray dryer • Establish additional raw material sources • Further develop Chinese infant formula relationships to prepare for the proposed new man
Slide 12: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s